Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
Eidos' $106 million IPO comes on the heels of a $64 million series B and will support phase 2 and phase 3 trials of its TTR amyloidosis drug.
Anika's hopes of a mid-2019 U.S. approval for arthritis drug Cingal are dashed by a late-stage trial miss, but it's not giving up on the project.
Implementation guidelines to support GxP in the cloud
The MPM Capital-led series B tees iTeos up to start dosing patients with an adenosine A2A antagonist later this year.
TG Therapeutics will fund and run early-phase clinical trials of the treatment for hematologic B-cell malignancies.
This informative eBook explores technology currently being used to improve clinical trial efficiency, while also offering a peek into the emerging technologies…
The data, taken from three patients, showed a 38% increase in a muscle protein that boys with DMD usually lack.
Vertex's newly expanded site covers 170,000 square feet, boosting Vertex’s ability to hunt for the next generation of blockbusters.
Can-Fite won’t get a readout from its midstage trial of liver cancer drug namodenoson as soon as hoped, but says the data so far are looking good.
Syncona committed £85 million to Freeline, maintaining a big stake in a biotech that aims to redefine treatment of hemophilia B and Fabry disease.
Longtime Cowen analyst Eric Schmidt is joining Arie Belldegrun's latest CAR-T startup, Allogene.
Medivir's hopes of starting a pivotal trial of its HDAC inhibitor in lymphoma this year have hit a snag as it can't agree on a design with the FDA.